Status:
COMPLETED
Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
Lead Sponsor:
Changhai Hospital
Conditions:
Chronic HBV Infection
Drug Withdrawal
Eligibility:
All Genders
18-70 years
Brief Summary
The immune mechanism of the nucleos(t)ide analogs (NAs) in inhibiting HBV replication effectively while having a low sustained virus control rate after drug withdrawal is unclear. B cell immunity and ...
Eligibility Criteria
Inclusion
- 18 to 70 years old, no gender restriction, serum HBsAg positive than 6 months, can understand and sign informed consent, good compliance.
Exclusion
- coinfected with other hepatotropic virus such as hepatitis C virus,hepatitis D -virus,hepatitis E and hepatitis A etc; coinfected with HIV, markers such as ceruloplasmin, anti-nuclear antibodies and anti-mitochondrial antibodies for co-existent autoimmune and metabolic liver diseases were positive, with hepatocellular carcinoma(HCC) with uncontrollable extrehepatic disease, received glucocorticoid or other immune inhibitor therapy, pregnancy
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 20 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06029634
Start Date
July 1 2020
End Date
August 20 2023
Last Update
September 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai hospital
Shanghai, China, 200433